Martin UJ, Fuhr R, Forte P, et al. - Researchers conducted this open-label AMES study to compare the pharmacokinetic exposure following a single subcutaneous dose of benralizumab 30 mg using either autoinjectors (AI) or accessorized prefilled syringes (APFS). The study sample consisted of 180 healthy adult men and women. Participants in the study were randomized to one of two device (AI or APFS) and three injection site (upper arm, abdomen, or thigh) combinations. Among AI and APFS, the pharmacokinetic response to benralizumab was similar. With both devices, consistent blood eosinophil count reduction was identified. Such findings endorse the administration of benralizumab with either AI or APFS, offering patients and physicians increased choice, flexibility, and convenience for potential at-home delivery.